![](https://financialmodelingprep.com/image-stock/ABVC.png)
ABVC BioPharma, Inc. (ABVC)
ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.
$8.19M
Dr. Howard Doong M.D., Ph.D.
28.00
Fremont, CA
May 15, 2013
-0.40
$-1.66
0.11
0.33
-8,339.01%
-0.65
0.00
0.89
59.29
0.33
-77.73%
-132.83%
Similar stocks (17)
Eledon Pharmaceuticals, Inc.
ELDN
Aileron Therapeutics, Inc.
ALRN
Nutriband Inc.
NTRB
Anebulo Pharmaceuticals, Inc.
ANEB
Akari Therapeutics, Plc
AKTX
Longeveron Inc.
LGVN
SAB Biotherapeutics, Inc.
SABS
RenovoRx, Inc.
RNXT
Indaptus Therapeutics, Inc.
INDP
Forte Biosciences, Inc.
FBRX
Monopar Therapeutics Inc.
MNPR
Pasithea Therapeutics Corp.
KTTA
Quoin Pharmaceuticals, Ltd.
QNRX
Aditxt, Inc.
ADTX
Aridis Pharmaceuticals, Inc.
ARDS
Better Therapeutics, Inc.
BTTX
Evelo Biosciences, Inc.
EVLO
ETF Exposure (2)
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Extended Market Index Fund
VXF
0%
Similar stocks (17)
Eledon Pharmaceuticals, Inc.
ELDN
Aileron Therapeutics, Inc.
ALRN
Nutriband Inc.
NTRB
Anebulo Pharmaceuticals, Inc.
ANEB
Akari Therapeutics, Plc
AKTX
Longeveron Inc.
LGVN
SAB Biotherapeutics, Inc.
SABS
RenovoRx, Inc.
RNXT
Indaptus Therapeutics, Inc.
INDP
Forte Biosciences, Inc.
FBRX
Monopar Therapeutics Inc.
MNPR
Pasithea Therapeutics Corp.
KTTA
Quoin Pharmaceuticals, Ltd.
QNRX
Aditxt, Inc.
ADTX
Aridis Pharmaceuticals, Inc.
ARDS
Better Therapeutics, Inc.
BTTX
Evelo Biosciences, Inc.
EVLO
ETF Exposure (2)
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Extended Market Index Fund
VXF
0%